The estimated Net Worth of Bruce Peacock is at least $328 Tisíc dollars as of 3 December 2020. Mr. Peacock owns over 25,000 units of Ocular Therapeutix Inc stock worth over $211,000 and over the last 16 years he sold OCUL stock worth over $0. In addition, he makes $117,018 as Independent Director at Ocular Therapeutix Inc.
Bruce has made over 2 trades of the Ocular Therapeutix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of OCUL stock worth $127,250 on 3 December 2020.
The largest trade he's ever made was exercising 25,000 units of Ocular Therapeutix Inc stock on 3 December 2020 worth over $127,250. On average, Bruce trades about 1,295 units every 9 days since 2008. As of 3 December 2020 he still owns at least 25,000 units of Ocular Therapeutix Inc stock.
You can see the complete history of Mr. Peacock stock trades at the bottom of the page.
Bruce A. Peacock CPA serves as Independent Director of the Company. Mr. Peacock served as Executive Chairman at Carisma Therapeutics, a pre-clinical stage biotechnology company, from November 2016 to July 2019. From August 2013 to September 2014, Mr. Peacock served as the Chief Financial and Business Officer of Ophthotech Corporation, a biopharmaceutical company. He served as the Chief Business Officer of Ophthotech from September 2010 to August 2013. From May 2006 to June 2018, Mr. Peacock also served as a Venture Partner at SV Life Sciences. Mr. Peacock served as President and Chief Executive Officer of Alba Therapeutics, a biopharmaceutical company, from April 2008 to February 2011, and has served as Co-Chairman of the board of directors of Alba Therapeutics since April 2008. Prior to joining SV Life Sciences as a Venture Partner, Mr. Peacock served as Chief Executive Officer and a director of The Little Clinic, a medical care services company. Previously, Mr. Peacock served as President and Chief Executive Officer and a director of Adolor Corporation, a publicly-traded biotechnology company, as President, Chief Executive Officer and a member of the board of directors of Orthovita, Inc., a publicly-traded orthopedic biomaterials company, as Executive Vice President, Chief Operating Officer and a member of the board of directors of Cephalon, Inc., as Chief Financial Officer of Cephalon, Inc. and as Chief Financial Officer of Centocor, Inc. Mr. Peacock has served as a member of the boards of directors of Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.), a publicly-traded specialty pharmaceutical company, since September 2010, PanOptica Pharma, a private, clinical stage biopharmaceutical company, since March 2015Mr. Peacock holds a B.A. in Business Administration from Villanova University and is a certified public accountant.
As the Independent Director of Ocular Therapeutix Inc, the total compensation of Bruce Peacock at Ocular Therapeutix Inc is $117,018. There are 11 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
Bruce Peacock is 68, he's been the Independent Director of Ocular Therapeutix Inc since 2014. There are 1 older and 15 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Bruce's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE, BEDFORD,, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer a Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: